OM:HEXA B
OM:HEXA BElectronic

Hexagon (OM:HEXA B): Reassessing Valuation as Earnings Grow but Share Price Momentum Cools

Hexagon (OM:HEXA B) has been treading water lately, with the stock slipping over the past month despite steady revenue and faster growing net income. That disconnect naturally raises questions about valuation. See our latest analysis for Hexagon. Over the past year, Hexagon has delivered a modest positive total shareholder return while its recent 1 month and 1 week share price returns have slipped, suggesting momentum is cooling even as earnings trends remain supportive. If Hexagon’s slower...
OM:SECT B
OM:SECT BHealthcare Services

Sectra (OM:SECT B) Q2 2026: Margin‑Driven EPS Jump Reinforces Bullish Profitability Narrative

Sectra (OM:SECT B) has turned in a solid Q2 2026 print, posting revenue of SEK878 million and EPS of SEK0.77 as the latest chapter in a year where trailing twelve month revenue reached about SEK3.5 billion and EPS came in at roughly SEK3.35. The company has seen quarterly revenue move from SEK773 million in Q2 2025 to SEK878 million in Q2 2026, while EPS stepped up from SEK0.46 to SEK0.77 over the same period, pointing to healthier earnings power flowing through to the bottom line as margins...
OM:BETS B
OM:BETS BHospitality

Betsson (OM:BETS B): Valuation Check After Major Buyback, New Bond Issue and Early Redemption Move

Betsson (OM:BETS B) is making two clear capital allocation calls at once, stepping up its share buybacks while also refinancing debt and triggering early redemption of its 2023 and 2026 bonds. See our latest analysis for Betsson. Those buybacks and bond moves land after a choppy spell, with the share price at SEK 145.6 and a modestly positive year to date share price return. The three year total shareholder return of 103.35 percent suggests underlying momentum is still intact even if shorter...
OM:HUSQ B
OM:HUSQ BMachinery

How Husqvarna’s 2030 Cost‑Out and CO₂ Targets At Husqvarna (OM:HUSQ B) Has Changed Its Investment Story

Earlier this month, Husqvarna Group outlined its priorities through 2030, targeting 3–5% annual organic sales growth and a 60% cut in CO₂ emissions, backed by a cost-out program aiming for SEK 4.00 billion in yearly savings. Beyond efficiency, the plan signals a deeper shift toward combining financial discipline with sustainability metrics as equal yardsticks of success. We’ll now explore how this long-term cost-out program reshapes Husqvarna’s investment narrative and its path toward...
OM:PDX
OM:PDXEntertainment

How Investors Are Reacting To Paradox Interactive (OM:PDX) Launching Victoria 3: Iberian Twilight DLC

On 11 December 2025, Paradox Interactive released Victoria 3: Iberian Twilight, a US$9.99 immersion pack adding Spain- and Portugal-focused historical content, new mechanics, and visual upgrades to its grand strategy title. This new downloadable content deepens engagement in one of Paradox’s key live-service franchises, reinforcing its model of monetizing long-lived game communities. We’ll now assess how this fresh Iberian-themed Victoria 3 content drop feeds into Paradox Interactive’s...
OM:CLA B
OM:CLA BFood

Is Cloetta (OM:CLA B) Using CandyKing’s NYC Flagship to Quietly Reposition Its Global Brand Strategy?

CandyKing, part of Cloetta, announced on December 4, 2025 that it is opening a permanent Swedish candy store this week in New York City’s West Village, offering its full concept and exclusive products at 306 Bleecker Street. This U.S. flagship gives American consumers direct influence over the store’s evolving assortment, turning customer input into a core element of CandyKing’s offering. We’ll now examine how CandyKing’s New York flagship and U.S. expansion shape Cloetta’s investment...
OM:SOBI
OM:SOBIBiotechs

How Investors May Respond To Swedish Orphan Biovitrum (OM:SOBI) Aspaveli’s Positive EU Kidney-Disease Opinion

Swedish Orphan Biovitrum AB (Sobi) recently received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use recommending marketing authorisation of Aspaveli (pegcetacoplan) to treat adults and adolescents with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis across the European Union. If approved by the European Commission, Aspaveli would become the first authorised therapy for these rare, severe kidney diseases in patients 12...
OM:RUSTA
OM:RUSTAMultiline Retail

Assessing Rusta (OM:RUSTA) Valuation After Strong Q2, Nordic Online Rollout and Continued Store Expansion

Rusta (OM:RUSTA) just delivered a busy quarter, combining higher sales, stronger Q2 profits and fresh store openings with a full Nordic online rollout. This mix naturally puts the share in focus. See our latest analysis for Rusta. The market seems to be buying into that story, with the share price at SEK 82.05 after a punchy 1 month share price return of 25.84% and a 1 year total shareholder return of 16.50%. This suggests momentum is building as the earnings beat, new CEO announcement and...